Prevention of malaria in children: malaria vaccine RTS,S/AS01 (RTS,S) ; assets and limits.
Mots-clés :
Prevention, malaria, pediatrics, assets and limits, RTS, S vaccineRésumé
Despite the progress made, efforts to combat malaria face many challenges. The African region remains the most affected by malaria, with 95% of cases and 96% of deaths worldwide recorded there. Children are particularly vulnerable; nearly half a million African children die from malaria every year.
Consequently, the strategy to combat this endemic disease in several African regions necessarily involves an intensification of the means of prevention against malaria in conjunction with the existing active ingredients to cure the disease and also other means of prevention such as sleeping under the mosquito net impregnated with insecticide.
Among these means of prevention, there are anti-malaria vaccines, among which we cite RTS,S/AS01 (RTS,S), the assets and limits of which are discussed in this review of the literature. Efficacy and safety in reducing the number of pediatric hospitalizations for severe malaria and infant mortality constitute the major advantages of the RTS,S/AS01 (RTS,S) vaccine. While its limitations such as a limited supply of vaccines which, according to current forecasts, could fortunately be filled by the production of the new anti-malaria vaccine, R21 in this case.
And so today, the RTS,S/AS01 (RTS,S) malaria vaccine remains an effective and safe means of combating malaria in children.
Téléchargements
Références
Goffaux J. Notions d’écologie. Centre de Recherches Pédagogiques, Kinshasa, 1991.
Vaccins antipaludiques (RTS, S et R21) [internet]. Available on https://www.who.int/fr/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine#:~:text=Depuis%20le%202%20octobre%202023,l'%C3%A2ge%20de%205%20mois. [Published on October 17, 2023 and accessed on October 23, 2023]
L’OMS recommande un vaccin antipaludique novateur destiné aux enfants à risque [internet]. Available on https://www.un.org/africarenewal/fr/magazine/l%E2%80%99oms-recommande-un-vaccin-antipaludique-novateur-destin%C3%A9-aux-enfants-%C3%A0-risque. [Published on October 7, 2021 and accessed on October 24, 2023]
Vaccins : La pierre angulaire de la réduction du poids de la morbidité [internet]. Available on https://www.malariaconsortium.org/resources/publications/1652/vaccins--la-pierre-angulaire-de-la-r-duction-du-poids-de-la-morbidit#. [Published on November 22, 2022 and accessed on October 23, 2023]
Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, et al. A preliminary evaluation Of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997; 336: 86–91.
Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines. 2011 May ; 10(5) :589–99. [PubMed] [Google Scholar]
Mosquirix Product Information. 2015. Accessed on April 7, 2016. [Google Scholar]
Le vaccin contre le paludisme : une avancée majeure dans la lutte contre la maladie la plus meurtrière pour les enfants [internet]. Available on https://www.google.com/amp/s/www.bbc.com/afrique/region-66996422.amp. [Published on October 4, 2023 et accessed on October 23, 2023]
